Group 1 - The company announced a conditional agreement to acquire 100% of the issued share capital and loans of the target company, Aono Hong Kong, for a total consideration of HKD 22 million, which will result in the target company becoming an indirect wholly-owned subsidiary [1] - Following the acquisition, the company will hold a 37.5% equity interest in Beisheng Biotechnology, and the financial performance, assets, and liabilities of Beisheng will be accounted for using the equity method in the company's financial statements [1] - Beisheng Biotechnology specializes in strain design and fermentation process development, providing high-quality, convenient, and cost-effective technical services and related products for synthetic biology enterprises and traditional fermentation companies seeking to upgrade through synthetic biology technology [1][2] Group 2 - The company believes that the research and development of proprietary rights and technologies related to healthcare and beauty businesses is key to gaining a competitive advantage [2] - Current R&D focuses include a dual-protein water light needle using hyaluronic acid penetration enhancement technology, composite fillers targeting the temporal filler market, photo-activated collagen repair essence, and targeted anti-aging therapies using stem cell exosomes [2] - The acquisition of Beisheng Biotechnology is expected to enhance the efficiency of the company's R&D projects, reduce R&D costs, and accelerate the commercialization of R&D results [3]

朸濬国际(01355)发布公告，于2025年12月23日，本公司直接全资附属公司佳怡环球作为买方与卖方郑 彤女士订立买卖协议，卖方有条件同意出售而买方有条件同意购买销售股份(占目标公司奥诺香港已发 行股本的100%)及销售贷款，总作价为2200万港元。于完成后，目标公司将成为本公司的间接全资附属 公司及本公司将持有倍生生物的37.5%权益，倍生生物集团的财务业绩、资产及负债将以权益法会计处 理计入在本集团的财务报表。 倍生生物是专注于菌株设计和发酵工艺开发的合成生物基础设施供应商，为合成生物企业、生物医药企 业及希望利用合成生物技术实现产业升级的传统发酵企业提供更高品质、更便捷、更低成本的技术服务 及相关产品。 本集团认为，医疗保健及美容业务相关专有权利与技术的研发是取得竞争优势的关键。本集团目前的研 发重点领域包括：III型胶原蛋白-透明质酸"双蛋白"水光针，主要采用透明质酸渗透增强技术，以重组 III型胶原蛋白+乙酰化透明质酸(AcHA)为复合成分，提高透皮吸收效率，从而实现即时填充+长期再生; 羟基磷灰石/胶原蛋白复合填料，瞄准颞部填料这一庞大市场;光电激活型胶原蛋白修护精华，主要目标 是开发含有热敏/ ...

Group 1 - The company, Puhua International (01355.HK), announced a conditional sale agreement with Zheng Tong, where the buyer, Jiayi Global Limited, will purchase 100% of the issued share capital of the target company, Ono Hong Kong Limited, for a total consideration of HKD 22 million [1] - Upon completion, Ono Hong Kong Limited will become an indirect wholly-owned subsidiary of the company, and the company will hold a 37.5% equity interest in Beisheng Biotechnology, with its financial performance, assets, and liabilities accounted for using the equity method in the group's financial statements [1] Group 2 - The company believes that the research and development of proprietary rights and technologies related to healthcare and beauty businesses is key to gaining a competitive advantage [2] - Current R&D focus areas include: (a) Type III collagen-hyaluronic acid "dual protein" water light needle, utilizing hyaluronic acid permeation enhancement technology to improve transdermal absorption efficiency; (b) Hydroxyapatite/collagen composite fillers targeting the large market for temporal fillers; (c) Photoelectric activated collagen repair essence aimed at developing essence containing thermosensitive/photo-sensitive liposomes for precise repair; and (d) Stem cell exosome targeted anti-aging therapy focusing on developing freeze-dried exosome microspheres for targeted release and long-lasting repair [2]